Mitchell Finer

1.4k total citations
24 papers, 679 citations indexed

About

Mitchell Finer is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Mitchell Finer has authored 24 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Genetics and 9 papers in Oncology. Recurrent topics in Mitchell Finer's work include Virus-based gene therapy research (10 papers), CAR-T cell therapy research (7 papers) and RNA Interference and Gene Delivery (5 papers). Mitchell Finer is often cited by papers focused on Virus-based gene therapy research (10 papers), CAR-T cell therapy research (7 papers) and RNA Interference and Gene Delivery (5 papers). Mitchell Finer collaborates with scholars based in United States, Malaysia and Netherlands. Mitchell Finer's co-authors include Helga Boedtker, Qing Wang, Paul Doty, Sirpa Aho, James G. McArthur, Ryan McGuinness, Krisztina M. Zsebo, Margo R. Roberts, Keegan S. Cooke and Louis C. Gerstenfeld and has published in prestigious journals such as Nucleic Acids Research, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Mitchell Finer

23 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitchell Finer United States 15 352 328 264 170 98 24 679
M H Finer United States 12 390 1.1× 245 0.7× 144 0.5× 104 0.6× 95 1.0× 13 630
P.G. Strauss Germany 16 479 1.4× 189 0.6× 191 0.7× 212 1.2× 38 0.4× 32 868
Mary DeRome United States 15 397 1.1× 83 0.3× 124 0.5× 55 0.3× 70 0.7× 23 676
Joan C. Rosenbloom United States 15 416 1.2× 329 1.0× 54 0.2× 91 0.5× 88 0.9× 16 839
Sylvie Mathieu France 13 350 1.0× 82 0.3× 80 0.3× 117 0.7× 56 0.6× 24 731
Katsuyoshi Habiro Japan 10 260 0.7× 135 0.4× 103 0.4× 489 2.9× 54 0.6× 14 798
Bruce A. Boswell United States 16 458 1.3× 257 0.8× 47 0.2× 63 0.4× 111 1.1× 20 760
PD Robbins United States 10 369 1.0× 373 1.1× 247 0.9× 351 2.1× 26 0.3× 12 1.1k
C. Scott Swindle United States 12 370 1.1× 121 0.4× 139 0.5× 148 0.9× 93 0.9× 15 717
Sarah Hale United Kingdom 13 580 1.6× 397 1.2× 196 0.7× 65 0.4× 20 0.2× 20 913

Countries citing papers authored by Mitchell Finer

Since Specialization
Citations

This map shows the geographic impact of Mitchell Finer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Finer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Finer more than expected).

Fields of papers citing papers by Mitchell Finer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Finer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Finer. The network helps show where Mitchell Finer may publish in the future.

Co-authorship network of co-authors of Mitchell Finer

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Finer. A scholar is included among the top collaborators of Mitchell Finer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Finer. Mitchell Finer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kennedy, Edward M., Jennifer S. Lee, Damian G. Deavall, et al.. (2020). Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability. Molecular Therapy — Oncolytics. 18. 476–490. 20 indexed citations
2.
Kennedy, Edward M., Prajna Behera, Brian B. Haines, et al.. (2019). Abstract 1455: Design of ONCR-177 base vector, a next generation oncolytic herpes simplex virus type-1, optimized for robust oncolysis, transgene expression and tumor-selective replication. Cancer Research. 79(13_Supplement). 1455–1455. 5 indexed citations
3.
4.
Heffner, Garrett C., Melissa Bonner, Francis J. Pierciey, et al.. (2016). 229. PGE2 Increases Lentiviral Vector Transduction Efficiency of Human HSC. Molecular Therapy. 24. S89–S90. 3 indexed citations
5.
Hanna, Michael G., Herbert Hoover, Herbert M. Pinedo, & Mitchell Finer. (2006). Active Specific Immunotherapy with Autologous Tumor cell vaccines for Stage II Colon Cancer: Logistics, Efficacy, Safety and Immunological Pharmacodynamics. Human Vaccines. 2(4). 185–191. 18 indexed citations
6.
Finer, Mitchell. (2003). The RNase Protection Assay. Humana Press eBooks. 7. 283–296. 2 indexed citations
7.
Sheu, Eric G., et al.. (2003). The Gene Pill and its therapeutic applications.. PubMed. 5(4). 420–7. 4 indexed citations
8.
Hokanson, Craig A., et al.. (2003). Hybrid Yeast–Bacteria Cloning System Used to Capture and Modify Adenoviral and Nonviral Genomes. Human Gene Therapy. 14(4). 329–339. 8 indexed citations
9.
Patel, Salil D., Марина Москаленко, Douglas H. Smith, et al.. (2000). T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Therapy. 7(8). 1127–1134. 19 indexed citations
10.
McGuinness, Ryan, Ying Ge, Salil D. Patel, et al.. (1999). Anti-Tumor Activity of Human T Cells Expressing the CC49-zeta Chimeric Immune Receptor. Human Gene Therapy. 10(2). 165–173. 83 indexed citations
11.
Farson, Deborah, Ryan McGuinness, Kay Limoli, et al.. (1999). Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols. The Journal of Gene Medicine. 1(3). 195–209. 23 indexed citations
12.
Farson, Deborah, Ryan McGuinness, Kay Limoli, et al.. (1999). Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols. The Journal of Gene Medicine. 1(3). 195–209.
13.
Roberts, Margo R., Keegan S. Cooke, Kevin M. Smith, et al.. (1998). Antigen-Specific Cytolysis by Neutrophils and NK Cells Expressing Chimeric Immune Receptors Bearing ζ or γ Signaling Domains. The Journal of Immunology. 161(1). 375–384. 55 indexed citations
14.
Wang, Qing & Mitchell Finer. (1996). Second–generation adenovirus vectors. Nature Medicine. 2(6). 714–716. 96 indexed citations
15.
Finer, Mitchell, Helga Boedtker, & Paul Doty. (1987). Construction and characterization of cDNA clones encoding the 5′ end of the chicken pro α1(I) collagen mRNA. Gene. 56(1). 71–78. 15 indexed citations
16.
Gerstenfeld, Louis C., Mitchell Finer, & Helga Boedtker. (1985). Altered β-Actin Gene Expression in Phorbol Myristate Acetate-Treated Chondrocytes and Fibroblasts. Molecular and Cellular Biology. 5(6). 1425–1433. 9 indexed citations
17.
Finer, Mitchell, Louis C. Gerstenfeld, Delano V. Young, Paul Doty, & Helga Boedtker. (1985). Collagen Expression in Embryonic Chicken Chondrocytes Treated with Phorbol Myristate Acetate. Molecular and Cellular Biology. 5(6). 1415–1424. 48 indexed citations
18.
Boedtker, Helga, Mitchell Finer, & Sirpa Aho. (1985). The Structure of the Chicken α2 Collagen Genea. Annals of the New York Academy of Sciences. 460(1). 85–116. 69 indexed citations
19.
Tate, Valerie, Mitchell Finer, Helga Boedtker, & Paul Doty. (1983). Chick proα2 (I) collagen gene; exon location and coding potential for the prepropeptide. Nucleic Acids Research. 11(1). 91–104. 48 indexed citations
20.
Finer, Mitchell, et al.. (1980). Cleavage and circularization of single-stranded DNA: a novel enzymatic activity ofφX174 A*protein. Nucleic Acids Research. 8(22). 5305–5316. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M H Finer Breakdown of academic impact, for papers by P.G. Strauss Breakdown of academic impact, for papers by Mary DeRome Breakdown of academic impact, for papers by Joan C. Rosenbloom Breakdown of academic impact, for papers by Sylvie Mathieu Breakdown of academic impact, for papers by Katsuyoshi Habiro Breakdown of academic impact, for papers by Bruce A. Boswell Breakdown of academic impact, for papers by PD Robbins Breakdown of academic impact, for papers by C. Scott Swindle Breakdown of academic impact, for papers by Sarah Hale
Rankless by CCL
2026